Caris Life Sciences Basel, Switzerland
He assumed this post in February 2009. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and healthcare informatics for personalized medicine. From 2003 to 2008 he founded the Biodesign Institute at ASU. In addition to his academic post he serves as chief executive of a consulting company, Health Technology Networks, which specializes in the application of genomic technologies and computing in healthcare. He serves on the board of directors of Monsanto, Exelixis and Caris Life Sciences and on the Scientific Advisory Boards for Synthetic Genomics and the A. Alfred Taubman Institute for Medical Research at the University of Michigan. From 1992 to 1999 he was chief science and technology officer and president, R&D of SmithKline Beecham (SB).